Soligenix, Inc. announced on September 4, 2025, the publication of data describing the extended stability of its ebolavirus vaccines, utilizing the proprietary ThermoVax® platform. The study demonstrated that bivalent and trivalent vaccines, formulated in a single vial, maintained two-year stability at temperatures up to 40°C (104°F) with equivalent potency.
This long-term thermostability is a critical advantage for vaccine distribution and stockpiling, particularly in virus-endemic countries in Africa and for strategic national biodefense reserves. The ThermoVax® platform eliminates the need for a cold chain, simplifying logistics and improving global vaccination efforts.
The publication, accepted in Vaccine, reinforces the ThermoVax® platform as a well-established thermostabilization strategy that enhances protein subunit vaccination technology. This advancement makes Soligenix's subunit vaccines competitive with other technologies that have more stringent cold-storage requirements, aiding in preparedness for future outbreaks and pandemics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.